Neumora Therapeutics IPO Presentation Deck
Important Disclosures
This presentation has been prepared by Neumora on a confidential basis and is made for informational purposes only. Any reproduction or distribution of this presentation, in
whole or in part, or the disclosure of any of its contents, without the prior consent of Neumora is prohibited. The information set forth herein does not purport to be complete or to
contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise.
This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. These forward-looking statement include, but are not limited to,
those regarding the Neumora's strategy, intellectual property matters, Neumora's clinical development plans and timelines, regulatory matters, and market size and opportunity.
The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us.
These statements are only predictions based upon our current expectations and projections about future events. Such statements reflect the current views of Neumora with
respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and
assumptions about Neumora, including, without limitation, risks inherent in developing therapeutic products, future results from Neumora's ongoing and planned clinical trials,
Neumora's ability to obtain adequate financing to fund its planned clinical trials and other expenses, trends in the industry, the legal and regulatory framework for the industry and
future expenditures. Although we have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking
statements, there may be other factors that cause results not to be as anticipated, estimated or intended. You should not rely on forward-looking statements as a prediction of
future events.
The assumptions used in the preparation of this presentation, although considered reasonable by us at the time of preparation, may prove to be incorrect. You are cautioned that
the information is based on assumptions as to many factors and that actual results may vary from the results projected and such variations may be material. Accordingly, you
should not place undue reliance on any forward-looking statements contained herein. We do not undertake to update any forward-looking statements, except in accordance with
applicable securities laws.
Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications and other data obtained from
third-party sources as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, it has not
independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources.
This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional
buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with Neumora Therapeutics, Inc ("Neumora," "we" or "us") and
determining whether such investors might have an interest in a securities offering contemplated by Neumora. No such offering is being made at this time. Any such offering of
securities will only be made by means of a registration statement (including a prospectus) filed with the U.S. Securities and Exchange Commission (the "SEC"), after such
registration statement becomes effective. No such registration statement has been filed, or become effective, as of the date of this communication. This presentation shall not
constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Confidential
2View entire presentation